OtherBasic Science Investigations

Biodistribution and Radiation Dosimetry of the Serotonin Transporter Ligand 11C-DASB Determined from Human Whole-Body PET

Jian-Qiang Lu, Masanori Ichise, Jeih-San Liow, Subroto Ghose, Doug Vines and Robert B. Innis
Journal of Nuclear Medicine September 2004, 45 (9) 1555-1559;

Article Figures & Data

Figures

  • FIGURE 1.
    FIGURE 1.

    Compressed whole-body planar emission images demonstrating biodistribution of radioactivity in a healthy subject 2, 5, 30, and 90 min after intravenous injection of 11C-DASB.

  • FIGURE 2.
    FIGURE 2.

    Time–activity curves for 11C-DASB determined from serial PET of organs. (A) Graph showing data expressed as mean ± SD for 7 subjects and not corrected for radioactive decay. (B) Graph showing data expressed as averages for 7 subjects and not corrected for radioactive decay.

  • FIGURE 3.
    FIGURE 3.

    Cumulative urinary excretion of decay-corrected radioactivity after intravenous administration of 11C-DASB to 7 healthy subjects. Data points reflect actual radioactivity measured for bladder by PET. Solid line is monoexponential fitting with Prism software (version 3.0; GraphPad Software Inc.) for the averages of 7 subjects. The fraction excreted via urine reached a maximal (asymptotic) value of approximately 12%, with a half-life of 51 min.

Tables

  • TABLE 1

    Residence Times Calculated from Whole-Body Images of 7 Subjects

    OrganResidence time (h)
    Brain0.024 ± 0.005
    Gallbladder0.003 ± 0.002
    Heart0.017 ± 0.006
    Kidneys0.009 ± 0.004
    Liver0.030 ± 0.007
    Lungs0.126 ± 0.035
    Spleen0.004 ± 0.001
    Remainder of body0.252 ± 0.033

    • Values are means ± SDs for the 7 subjects.

  • TABLE 2

    Radiation Dose Estimates for 11C-DASB

    Target organmGy/MBqrad/mCi
    Adrenals3.16E-031.17E-02
    Brain5.77E-032.14E-02
    Breasts2.36E-038.73E-03
    Gallbladder wall9.27E-033.43E-02
    Lower large intestine wall2.11E-037.82E-03
    Small intestine2.18E-038.08E-03
    Stomach2.46E-039.09E-03
    Upper large intestine wall2.21E-038.19E-03
    Heart wall8.21E-033.04E-02
    Kidneys9.28E-033.43E-02
    Liver6.41E-032.37E-02
    Lungs3.28E-021.21E-01
    Muscle2.09E-037.72E-03
    Ovaries2.18E-038.06E-03
    Pancreas3.03E-031.12E-02
    Red marrow2.33E-038.63E-03
    Bone surfaces2.25E-038.34E-03
    Skin1.60E-035.91E-03
    Spleen7.40E-032.74E-02
    Testes1.74E-036.44E-03
    Thymus2.98E-031.10E-02
    Thyroid2.06E-037.63E-03
    Urinary bladder wall1.20E-024.43E-02
    Uterus2.45E-039.05E-03
    Total body2.75E-031.02E-02
    mSv/MBqrem/mCi
    Effective dose equivalent8.01E-032.96E-02
    Effective dose6.98E-032.58E-02

    • Urine-voiding interval is 2.4 h.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section